OPC-34712
DrugTablet
NCT Number: NCT01360866
To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 3
Research Site, Gatineau, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Eligible subjects from Trials 331-10-227, 331-10-228 or 331-12-282:
Eligible subjects from other Phase 3, Double-blind, Brexpiprazole MDD trials:
Exclusion criteria
Tablet
Tablet
Other names: Lexapro
Capsule
Other names: Prozac
Controlled-release tablets
Other names: Paxil CR
Tablets
Other names: Zoloft
Delayed-release capsules
Other names: Cymbalta
Extended-release capsules
Other names: Effexor XR
Time frame: From screening to week 52/early termination
To assess the frequency and severity of AEs as the variables of safety and tolerability of brexpiprazole.
Time frame: From screening to week 52/early termination
The severity of illness for each participant was rated using the CGI-S . On the basis of the investigator answer to the question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: From screening to week 52/early termination
The efficacy of trial treatment was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the participant's condition at screening. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse and 7 = very much worse.
Time frame: From screening to week 52/early termination
The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on regular life responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains with scores from 0 = not at all, to 10 = extremely.
Scores of 5 and above were associated with significant functional impairment.
Time frame: From screening to week 52/early termination
The IDS-SR was a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of MDD. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 (best) to 84 (worst).
Under item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. If the number of items recorded is at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
Acronym: Orion
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02196506
Behavior, Behavioral Symptoms
Birmingham, Alabama, United States
View Trial DetailsNCT01727726
Behavior, Behavioral Symptoms
Birmingham, Alabama, United States
View Trial DetailsNCT01360632
Behavior, Behavioral Symptoms
Birmingham, Alabama, United States
View Trial DetailsNCT01360645
Behavior, Behavioral Symptoms
Arcadia, California, United States
View Trial Details